Antibody-drug conjugates can deliver chemotherapy directly to tumors but more than 95 percent of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity. Mythic Therapeutics FateControl technology improves the uptake of ADCs in cancerous cells while avoiding the release of their toxic payloads in healthy ones. This promises to increase efficacy of these therapies in a wide range of cancers without causing unacceptable side-effects. We spoke to Brian Fiske, co-founder, chief scientific officer of Mythic, about the challenges that have held back the benefits of ADCs, how the company’s FateControl technology addresses those, and how it is thinking of building a pipeline of ADCs across indications.
Engineering Off-the-Shelf Cell Therapies to Target Solid Tumors
Democratizing Drug Discovery
Scaling Genetic Counseling Services with AI
Programming Cell Therapies to Overcome Solid Tumor Defense Systems
Using Liquid Biopsies to Diagnose Infectious Diseases
Striking Hepatitis B at Its Core
Modulating Serotonin with Psychedelics to Treat Neuropsychiatric Conditions
A Procedural Therapy Seeks to Address Type 2 Diabetes at Its Root Cause
Building a Better Path to Neurotherapeutics
Taking a Portfolio Approach to Immuno-Oncology
Engineering Life to Reach New Worlds
Targeting Cancer Drug Side Effects at Their Source
Mapping the Universe of Human Proteins
Fighting Disease by Modulating the Translation of Proteins
Fixing Biopharma’s R&D Productivity by Taking a Cue from the Tech Industry
An Affordable and Widely Available Drug Offers Global Hope against COVID
A Gene Therapy to Program the Body to Produce a Treatment for Osteoarthritis
A Test for Data-Driven Drug Development
Bridging the Gulf Between the Promise and Reality of Precision Health
Using Synthetic Biology to Craft One-Time, Programmable mRNA Therapeutics
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths